BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.

BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell. 2014 Sep 08; 26(3):428-442.

View in: PubMed

subject areas

Antineoplastic Agents
Catalytic Domain
Drug Resistance, Neoplasm
Fusion Proteins, bcr-abl
Humans
Imidazoles
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Molecular Dynamics Simulation
Mutation, Missense
Philadelphia Chromosome
Protein Binding
Protein Kinase Inhibitors
Pyridazines
Treatment Failure

authors with profiles

Richard A. Larson